这是一篇来自已证抗体库的有关人类 MSH2的综述，是根据60篇发表使用所有方法的文章归纳的。这综述旨在帮助来邦网的访客找到最适合MSH2 抗体。
MSH2 同义词: COCA1; FCC1; HNPCC; HNPCC1; LCFS2; hMSH2

赛默飞世尔
小鼠 单克隆（FE11）
  • 免疫印迹; 人类; 图 1s1c
赛默飞世尔 MSH2抗体（Thermo Fisher, 33-7900)被用于被用于免疫印迹在人类样本上 (图 1s1c). elife (2019) ncbi
小鼠 单克隆（FE11）
  • 免疫印迹基因敲除验证; 小鼠; 图 s2a
赛默飞世尔 MSH2抗体（Invitrogen, FE11)被用于被用于免疫印迹基因敲除验证在小鼠样本上 (图 s2a). Science (2019) ncbi
小鼠 单克隆（FE11）
  • 免疫组化-石蜡切片; 人类; 表 2
赛默飞世尔 MSH2抗体（Invitrogen, FE11)被用于被用于免疫组化-石蜡切片在人类样本上 (表 2). Am J Surg (2017) ncbi
小鼠 单克隆（FE11）
  • 免疫组化-石蜡切片; 人类; 1:50; 图 s1
赛默飞世尔 MSH2抗体（Invitrogen, 33-7900)被用于被用于免疫组化-石蜡切片在人类样本上浓度为1:50 (图 s1). BMC Cancer (2016) ncbi
小鼠 单克隆（FE11）
  • 免疫组化-石蜡切片; 人类; 1:200
赛默飞世尔 MSH2抗体（Invitrogen, FE11)被用于被用于免疫组化-石蜡切片在人类样本上浓度为1:200. PLoS ONE (2015) ncbi
小鼠 单克隆（FE11）
  • 免疫组化-石蜡切片; 人类
赛默飞世尔 MSH2抗体（生活技术, FE11)被用于被用于免疫组化-石蜡切片在人类样本上. Obstet Gynecol Sci (2015) ncbi
小鼠 单克隆（FE11）
  • 免疫组化; 人类; 1:100
赛默飞世尔 MSH2抗体（Invitrogen, FE11)被用于被用于免疫组化在人类样本上浓度为1:100. Appl Immunohistochem Mol Morphol (2016) ncbi
小鼠 单克隆（FE11）
  • 免疫组化-石蜡切片; 人类; 1:200
赛默飞世尔 MSH2抗体（Zymed/Invitrogen, FE11)被用于被用于免疫组化-石蜡切片在人类样本上浓度为1:200. Genet Test Mol Biomarkers (2014) ncbi
小鼠 单克隆（FE11）
  • 免疫组化; 人类; 1:100; 图 1
赛默飞世尔 MSH2抗体（Invitrogen, FE11)被用于被用于免疫组化在人类样本上浓度为1:100 (图 1). Cancer Genet (2013) ncbi
小鼠 单克隆（FE11）
  • 免疫组化-石蜡切片; 人类; 图 2
赛默飞世尔 MSH2抗体（Invitrogen, FE11)被用于被用于免疫组化-石蜡切片在人类样本上 (图 2). Pathol Res Pract (2014) ncbi
小鼠 单克隆（FE11）
  • 免疫组化; 人类; 1:250; 表 1
赛默飞世尔 MSH2抗体（Invitrogen, clone FE11)被用于被用于免疫组化在人类样本上浓度为1:250 (表 1). PLoS ONE (2013) ncbi
小鼠 单克隆（FE11）
  • 免疫印迹; 人类; 图 7
赛默飞世尔 MSH2抗体（Invitrogen, 33-7900)被用于被用于免疫印迹在人类样本上 (图 7). J Agric Food Chem (2012) ncbi
小鼠 单克隆（FE11）
  • 免疫组化-石蜡切片; 人类; 1:200; 表 2
赛默飞世尔 MSH2抗体（Zymed, FE11)被用于被用于免疫组化-石蜡切片在人类样本上浓度为1:200 (表 2). Anticancer Res (2012) ncbi
小鼠 单克隆（FE11）
  • 免疫组化-石蜡切片; 人类; 图 3
赛默飞世尔 MSH2抗体（ZYMED, FE11)被用于被用于免疫组化-石蜡切片在人类样本上 (图 3). Leuk Lymphoma (2013) ncbi
小鼠 单克隆（FE11）
  • 免疫组化-石蜡切片; 人类; 图 3
赛默飞世尔 MSH2抗体（Zymed, FE11)被用于被用于免疫组化-石蜡切片在人类样本上 (图 3). Oral Oncol (2012) ncbi
小鼠 单克隆（FE11）
  • 免疫组化-石蜡切片; 人类
赛默飞世尔 MSH2抗体（Zymed, FE11)被用于被用于免疫组化-石蜡切片在人类样本上. Hum Pathol (2011) ncbi
小鼠 单克隆（FE11）
  • 免疫组化-石蜡切片; 人类; 1:400; 图 4
赛默飞世尔 MSH2抗体（Zymed, FE11)被用于被用于免疫组化-石蜡切片在人类样本上浓度为1:400 (图 4). Cancer Cell (2010) ncbi
小鼠 单克隆（FE11）
  • 免疫组化-石蜡切片; 人类
赛默飞世尔 MSH2抗体（Zymed, FE11)被用于被用于免疫组化-石蜡切片在人类样本上. Fam Cancer (2010) ncbi
小鼠 单克隆（FE11）
  • 免疫组化-石蜡切片; 人类; 1:100
赛默飞世尔 MSH2抗体（Zymed Laboratories, FE11)被用于被用于免疫组化-石蜡切片在人类样本上浓度为1:100. J Clin Endocrinol Metab (2009) ncbi
小鼠 单克隆（FE11）
  • 免疫组化-石蜡切片; 人类; 1:200; 图 2
赛默飞世尔 MSH2抗体（Zymed, FE11)被用于被用于免疫组化-石蜡切片在人类样本上浓度为1:200 (图 2). Oral Surg Oral Med Oral Pathol Oral Radiol Endod (2009) ncbi
小鼠 单克隆（FE11）
  • 免疫组化-石蜡切片; 人类; 1:150
赛默飞世尔 MSH2抗体（Zymed, FE11)被用于被用于免疫组化-石蜡切片在人类样本上浓度为1:150. Gynecol Oncol (2009) ncbi
小鼠 单克隆（FE11）
  • 免疫组化-石蜡切片; 人类; 1:200
赛默飞世尔 MSH2抗体（Zymed, FE11)被用于被用于免疫组化-石蜡切片在人类样本上浓度为1:200. Cancer Epidemiol Biomarkers Prev (2009) ncbi
小鼠 单克隆（FE11）
  • 免疫组化-石蜡切片; 人类; 图 1
赛默飞世尔 MSH2抗体（Zymed, FE11)被用于被用于免疫组化-石蜡切片在人类样本上 (图 1). Oncol Rep (2008) ncbi
小鼠 单克隆（FE11）
  • 免疫组化-石蜡切片; 人类; 1:140
赛默飞世尔 MSH2抗体（Zymed Laboratories, FE11)被用于被用于免疫组化-石蜡切片在人类样本上浓度为1:140. APMIS (2008) ncbi
小鼠 单克隆（FE11）
  • 免疫组化-石蜡切片; 人类; 1:250; 图 1
赛默飞世尔 MSH2抗体（Zymed, FE11)被用于被用于免疫组化-石蜡切片在人类样本上浓度为1:250 (图 1). Oncol Rep (2008) ncbi
小鼠 单克隆（FE11）
  • 免疫组化-石蜡切片; 人类
赛默飞世尔 MSH2抗体（Zymed, FE11)被用于被用于免疫组化-石蜡切片在人类样本上. Int J Cancer (2008) ncbi
小鼠 单克隆（FE11）
  • 免疫组化-石蜡切片; 人类; 1:100
赛默飞世尔 MSH2抗体（Zymed Laboratories, FE11)被用于被用于免疫组化-石蜡切片在人类样本上浓度为1:100. Acta Oncol (2008) ncbi
小鼠 单克隆（FE11）
  • 免疫组化-石蜡切片; 人类; 1:400; 图 1
赛默飞世尔 MSH2抗体（Zymed, FE11)被用于被用于免疫组化-石蜡切片在人类样本上浓度为1:400 (图 1). Mod Pathol (2006) ncbi
小鼠 单克隆（FE11）
  • 免疫组化-石蜡切片; 人类
赛默飞世尔 MSH2抗体（Zymed, FE11)被用于被用于免疫组化-石蜡切片在人类样本上. Int J Gynecol Cancer (2006) ncbi
小鼠 单克隆（FE11）
  • 免疫组化; 人类; 1:100
赛默飞世尔 MSH2抗体（Zymed, FE11)被用于被用于免疫组化在人类样本上浓度为1:100. Fam Cancer (2005) ncbi
小鼠 单克隆（FE11）
  • 免疫组化-石蜡切片; 人类
赛默飞世尔 MSH2抗体（Zymed, FE11)被用于被用于免疫组化-石蜡切片在人类样本上. Am J Surg Pathol (2005) ncbi
小鼠 单克隆（FE11）
  • 免疫组化-石蜡切片; 人类
赛默飞世尔 MSH2抗体（Zymed, FE11)被用于被用于免疫组化-石蜡切片在人类样本上. Clin Cancer Res (2005) ncbi
小鼠 单克隆（FE11）
  • 免疫组化; 人类; 1:20
赛默飞世尔 MSH2抗体（Zymed, FE11)被用于被用于免疫组化在人类样本上浓度为1:20. Int J Cancer (2005) ncbi
小鼠 单克隆（FE11）
  • 免疫组化-石蜡切片; 人类; 1:400
赛默飞世尔 MSH2抗体（Zymed, FE11)被用于被用于免疫组化-石蜡切片在人类样本上浓度为1:400. Anticancer Res (2004) ncbi
小鼠 单克隆（FE11）
  • 免疫组化-石蜡切片; 人类; 1:400
赛默飞世尔 MSH2抗体（Zymed, FE11)被用于被用于免疫组化-石蜡切片在人类样本上浓度为1:400. Am J Pathol (2004) ncbi
小鼠 单克隆（FE11）
  • 免疫组化-石蜡切片; 人类; 1:400; 图 4
赛默飞世尔 MSH2抗体（Zymed, FE11)被用于被用于免疫组化-石蜡切片在人类样本上浓度为1:400 (图 4). Clin Cancer Res (2004) ncbi
艾博抗（上海）贸易有限公司
domestic rabbit 单克隆（SP46）
  • 免疫印迹基因敲除验证; 犬; 1:50; 图 6
艾博抗（上海）贸易有限公司 MSH2抗体（Abcam, SP46)被用于被用于免疫印迹基因敲除验证在犬样本上浓度为1:50 (图 6). J Vet Intern Med (2022) ncbi
domestic rabbit 单克隆（EPR3943）
  • 免疫印迹; 人类; 图 s1
艾博抗（上海）贸易有限公司 MSH2抗体（Abcam, ab92473)被用于被用于免疫印迹在人类样本上 (图 s1). Aging (Albany NY) (2021) ncbi
domestic rabbit 多克隆
  • 免疫印迹基因敲除验证; 小鼠; 1:10,000; 图 4
艾博抗（上海）贸易有限公司 MSH2抗体（Abcam, ab70270)被用于被用于免疫印迹基因敲除验证在小鼠样本上浓度为1:10,000 (图 4). PLoS Genet (2016) ncbi
赛信通（上海）生物试剂有限公司
domestic rabbit 单克隆（D24B5）
  • 免疫印迹; 小鼠; 1:1000; 图 3d
  • 免疫印迹; 人类; 1:1000; 图 4b
赛信通（上海）生物试剂有限公司 MSH2抗体（Cell Signaling, 2017)被用于被用于免疫印迹在小鼠样本上浓度为1:1000 (图 3d) 和 被用于免疫印迹在人类样本上浓度为1:1000 (图 4b). Adv Sci (Weinh) (2022) ncbi
domestic rabbit 单克隆（D24B5）
  • 免疫组化; 小鼠; 1:500
赛信通（上海）生物试剂有限公司 MSH2抗体（Cell Signaling Technology, 2017)被用于被用于免疫组化在小鼠样本上浓度为1:500. JCI Insight (2020) ncbi
小鼠 单克隆（3A2）
  • reverse phase protein lysate microarray; 人类; 图 st6
赛信通（上海）生物试剂有限公司 MSH2抗体（CST, 2850)被用于被用于reverse phase protein lysate microarray在人类样本上 (图 st6). Cancer Cell (2017) ncbi
小鼠 单克隆（3A2）
  • reverse phase protein lysate microarray; 人类; 图 3a
赛信通（上海）生物试剂有限公司 MSH2抗体（Cell Signaling, 2850)被用于被用于reverse phase protein lysate microarray在人类样本上 (图 3a). Nature (2017) ncbi
domestic rabbit 单克隆（D24B5）
  • 免疫印迹; 人类; 图 s3
赛信通（上海）生物试剂有限公司 MSH2抗体（Signaling Technology, 2017)被用于被用于免疫印迹在人类样本上 (图 s3). J Cell Mol Med (2016) ncbi
domestic rabbit 单克隆（D24B5）
  • 免疫印迹; 人类; 1:1000; 图 1g
赛信通（上海）生物试剂有限公司 MSH2抗体（Cell signalling, 2,017)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 1g). Nat Commun (2015) ncbi
小鼠 单克隆（3A2）
  • 免疫印迹; 人类; 1:1000; 图 2a
赛信通（上海）生物试剂有限公司 MSH2抗体（Cell signaling, 2850)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 2a). Oncotarget (2016) ncbi
domestic rabbit 单克隆（D24B5）
  • 免疫组化-石蜡切片; 人类; 1:200
  • 免疫印迹; 人类
赛信通（上海）生物试剂有限公司 MSH2抗体（Cell Signaling Technologies, 2017S)被用于被用于免疫组化-石蜡切片在人类样本上浓度为1:200 和 被用于免疫印迹在人类样本上. PLoS ONE (2013) ncbi
丹科医疗器械技术服务（上海）有限公司
小鼠 单克隆（FE11）
  • 免疫细胞化学; 人类; 1:50; 图 2d
丹科医疗器械技术服务（上海）有限公司 MSH2抗体（DakoCorporation, FE11)被用于被用于免疫细胞化学在人类样本上浓度为1:50 (图 2d). Arch Oral Biol (2017) ncbi
小鼠 单克隆（FE11）
  • 免疫组化-石蜡切片; 人类; 1:50; 表 1
丹科医疗器械技术服务（上海）有限公司 MSH2抗体（Dako, M3639)被用于被用于免疫组化-石蜡切片在人类样本上浓度为1:50 (表 1). Br J Cancer (2016) ncbi
Cell Marque
小鼠 单克隆（G219-1129）
  • 免疫组化; 人类; 1:700; 图 1, 2a, 2b
Cell Marque MSH2抗体（Cell Marque, G219?C1129)被用于被用于免疫组化在人类样本上浓度为1:700 (图 1, 2a, 2b). Acta Neuropathol Commun (2020) ncbi
徕卡显微系统(上海)贸易有限公司
单克隆（25D12）
  • 免疫组化-石蜡切片; 人类; 1:50; 表 1
徕卡显微系统(上海)贸易有限公司 MSH2抗体（Novocastra, PA0057)被用于被用于免疫组化-石蜡切片在人类样本上浓度为1:50 (表 1). ESMO Open (2022) ncbi
单克隆（25D12）
  • 免疫组化-石蜡切片; 大鼠; 1:300; 图 s6b
徕卡显微系统(上海)贸易有限公司 MSH2抗体（Leica Microsystems, PA0057)被用于被用于免疫组化-石蜡切片在大鼠样本上浓度为1:300 (图 s6b). PLoS ONE (2017) ncbi
单克隆（25D12）
  • 免疫组化-石蜡切片; 人类; 1:50
徕卡显微系统(上海)贸易有限公司 MSH2抗体（Novocastra, 25D12)被用于被用于免疫组化-石蜡切片在人类样本上浓度为1:50. APMIS (2015) ncbi
单克隆（25D12）
  • 免疫组化; 人类; 1:100
徕卡显微系统(上海)贸易有限公司 MSH2抗体（Novocastra, 25D12)被用于被用于免疫组化在人类样本上浓度为1:100. Arch Dermatol Res (2015) ncbi
单克隆（25D12）
  • 免疫组化-石蜡切片; 人类; 1:100
徕卡显微系统(上海)贸易有限公司 MSH2抗体（Novocastra Lab, 25D12)被用于被用于免疫组化-石蜡切片在人类样本上浓度为1:100. PLoS ONE (2014) ncbi
碧迪BD
小鼠 单克隆（G219-1129）
  • 其他; 人类; 图 st1
碧迪BD MSH2抗体（BD, G219-1129)被用于被用于其他在人类样本上 (图 st1). Mol Cell Proteomics (2016) ncbi
小鼠 单克隆（G219-1129）
  • 免疫印迹; 人类; 1:1000; 图 1
碧迪BD MSH2抗体（BD Biosciences, 556349)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 1). Nucleic Acids Res (2016) ncbi
小鼠 单克隆（G219-1129）
  • 免疫印迹; 人类
碧迪BD MSH2抗体（BD Biosciences, 556349)被用于被用于免疫印迹在人类样本上. J Biol Chem (2014) ncbi
小鼠 单克隆（G219-1129）
  • 免疫组化-石蜡切片; 人类; 1:20
碧迪BD MSH2抗体（Biosciences Company, 556349)被用于被用于免疫组化-石蜡切片在人类样本上浓度为1:20. BMC Surg (2014) ncbi
小鼠 单克隆（G219-1129）
  • 免疫组化-石蜡切片; 人类; 1:100
碧迪BD MSH2抗体（BD Pharmingen, G219-1129)被用于被用于免疫组化-石蜡切片在人类样本上浓度为1:100. BMC Gastroenterol (2013) ncbi
文章列表
  1. Inanaga S, Igase M, Sakai Y, Hagimori K, Sunahara H, Horikirizono H, et al. Relationship of microsatellite instability to mismatch repair deficiency in malignant tumors of dogs. J Vet Intern Med. 2022;36:1760-1769 pubmed 出版商
  2. Kumar D, Das M, Oberg A, Sahoo D, Wu P, Sauceda C, et al. Hepatocyte Deletion of IGF2 Prevents DNA Damage and Tumor Formation in Hepatocellular Carcinoma. Adv Sci (Weinh). 2022;9:e2105120 pubmed 出版商
  3. Simbolo M, Centonze G, Ali G, Garzone G, Taormina S, Sabella G, et al. Integrative molecular analysis of combined small-cell lung carcinomas identifies major subtypes with different therapeutic opportunities. ESMO Open. 2022;7:100308 pubmed 出版商
  4. Zhou Z, Tan F, Pei Q, Li C, Zhou Y, Li Y, et al. lncRNA SNHG4 modulates colorectal cancer cell cycle and cell proliferation through regulating miR-590-3p/CDK1 axis. Aging (Albany NY). 2021;13:9838-9858 pubmed 出版商
  5. Li H, Lu C, Zhang H, Hu Q, Zhang J, Cuevas I, et al. A PoleP286R mouse model of endometrial cancer recapitulates high mutational burden and immunotherapy response. JCI Insight. 2020;5: pubmed 出版商
  6. McCord M, Steffens A, Javier R, Kam K, McCortney K, Horbinski C. The efficacy of DNA mismatch repair enzyme immunohistochemistry as a screening test for hypermutated gliomas. Acta Neuropathol Commun. 2020;8:15 pubmed 出版商
  7. Pech M, Fong L, Villalta J, Chan L, Kharbanda S, O Brien J, et al. Systematic identification of cancer cell vulnerabilities to natural killer cell-mediated immune surveillance. elife. 2019;8: pubmed 出版商
  8. Mandal R, Samstein R, Lee K, Havel J, Wang H, Krishna C, et al. Genetic diversity of tumors with mismatch repair deficiency influences anti-PD-1 immunotherapy response. Science. 2019;364:485-491 pubmed 出版商
  9. Connolly N, Stokum J, Schneider C, Ozawa T, Xu S, Galisteo R, et al. Genetically engineered rat gliomas: PDGF-driven tumor initiation and progression in tv-a transgenic rats recreate key features of human brain cancer. PLoS ONE. 2017;12:e0174557 pubmed 出版商
  10. Cherniack A, Shen H, Walter V, Stewart C, Murray B, Bowlby R, et al. Integrated Molecular Characterization of Uterine Carcinosarcoma. Cancer Cell. 2017;31:411-423 pubmed 出版商
  11. . Integrated genomic and molecular characterization of cervical cancer. Nature. 2017;543:378-384 pubmed 出版商
  12. Massalou D, Benizri E, Chevallier A, Duranton Tanneur V, Pedeutour F, Benchimol D, et al. Peritoneal carcinomatosis of colorectal cancer: novel clinical and molecular outcomes. Am J Surg. 2017;213:377-387 pubmed 出版商
  13. Alves M, Carta C, de Barros P, Issa J, Nunes F, Almeida J. Repair genes expression profile of MLH1, MSH2 and ATM in the normal oral mucosa of chronic smokers. Arch Oral Biol. 2017;73:60-65 pubmed 出版商
  14. Ah Koon L, Lesage D, Lemadre E, Souissi I, Fagard R, Varin Blank N, et al. Cellular response to alkylating agent MNNG is impaired in STAT1-deficients cells. J Cell Mol Med. 2016;20:1956-65 pubmed 出版商
  15. Zhao X, Lokanga R, Allette K, Gazy I, Wu D, Usdin K. A MutS?-Dependent Contribution of MutS? to Repeat Expansions in Fragile X Premutation Mice?. PLoS Genet. 2016;12:e1006190 pubmed 出版商
  16. Koussounadis A, Langdon S, Um I, Kay C, Francis K, Harrison D, et al. Dynamic modulation of phosphoprotein expression in ovarian cancer xenograft models. BMC Cancer. 2016;16:205 pubmed 出版商
  17. Park J, Powell A, Roxburgh C, Horgan P, McMillan D, Edwards J. Mismatch repair status in patients with primary operable colorectal cancer: associations with the local and systemic tumour environment. Br J Cancer. 2016;114:562-70 pubmed 出版商
  18. Kanderová V, Kuzilkova D, Stuchly J, Vaskova M, Brdicka T, Fiser K, et al. High-resolution Antibody Array Analysis of Childhood Acute Leukemia Cells. Mol Cell Proteomics. 2016;15:1246-61 pubmed 出版商
  19. Kim K, Wen X, Yang H, Kim W, Kang G. Prognostic Implication of M2 Macrophages Are Determined by the Proportional Balance of Tumor Associated Macrophages and Tumor Infiltrating Lymphocytes in Microsatellite-Unstable Gastric Carcinoma. PLoS ONE. 2015;10:e0144192 pubmed 出版商
  20. Ortega Atienza S, Wong V, Deloughery Z, Luczak M, Zhitkovich A. ATM and KAT5 safeguard replicating chromatin against formaldehyde damage. Nucleic Acids Res. 2016;44:198-209 pubmed 出版商
  21. Masuda Y, Takahashi H, Sato S, Tomomori Sato C, Saraf A, Washburn M, et al. TRIM29 regulates the assembly of DNA repair proteins into damaged chromatin. Nat Commun. 2015;6:7299 pubmed 出版商
  22. Maachani U, Tandle A, Shankavaram U, Kramp T, Camphausen K. Modulation of miR-21 signaling by MPS1 in human glioblastoma. Oncotarget. 2016;7:52912-52927 pubmed 出版商
  23. Shin S, Yu E, Lee Y, Song Y, Seong M, Park S. Characteristics of hereditary nonpolyposis colorectal cancer patients with double primary cancers in endometrium and colorectum. Obstet Gynecol Sci. 2015;58:112-6 pubmed 出版商
  24. Boulagnon C, Dudez O, Beaudoux O, Dalstein V, Kianmanesh R, Bouché O, et al. BRAFV600E Gene Mutation in Colonic Adenocarcinomas. Immunohistochemical Detection Using Tissue Microarray and Clinicopathologic Characteristics: An 86 Case Series. Appl Immunohistochem Mol Morphol. 2016;24:88-96 pubmed 出版商
  25. Gurzu S, Kádár Z, Sugimura H, Bara T, Hălmaciu I, Jung I. Gastric cancer in young vs old Romanian patients: immunoprofile with emphasis on maspin and mena protein reactivity. APMIS. 2015;123:223-33 pubmed 出版商
  26. Gurzu S, Ciortea D, Tamasi A, Golea M, Bodi A, Sahlean D, et al. The immunohistochemical profile of granular cell (Abrikossoff) tumor suggests an endomesenchymal origin. Arch Dermatol Res. 2015;307:151-7 pubmed 出版商
  27. Lin B, Gupta D, Heinen C. Human pluripotent stem cells have a novel mismatch repair-dependent damage response. J Biol Chem. 2014;289:24314-24 pubmed 出版商
  28. Koppensteiner R, Samartzis E, Noske A, von Teichman A, Dedes I, Gwerder M, et al. Effect of MRE11 loss on PARP-inhibitor sensitivity in endometrial cancer in vitro. PLoS ONE. 2014;9:e100041 pubmed 出版商
  29. Lee J, Cragun D, Thompson Z, Coppola D, Nicosia S, Akbari M, et al. Association between IHC and MSI testing to identify mismatch repair-deficient patients with ovarian cancer. Genet Test Mol Biomarkers. 2014;18:229-35 pubmed 出版商
  30. Baiocchi G, Portolani N, Vermi W, Baronchelli C, Gheza F, Zogno C, et al. Lynch syndrome from a surgeon perspective: retrospective study of clinical impact of mismatch repair protein expression analysis in colorectal cancer patients less than 50 years old. BMC Surg. 2014;14:9 pubmed 出版商
  31. Dadone B, Ambrosetti D, Carpentier X, Duranton Tanneur V, Burel Vandenbos F, Amiel J, et al. A renal metanephric adenoma showing both a 2p16e24 deletion and BRAF V600E mutation: a synergistic role for a tumor suppressor gene on chromosome 2p and BRAF activation?. Cancer Genet. 2013;206:347-52 pubmed
  32. Boulagnon C, Jazeron J, Diaz Cives A, Ehrhard F, Bouche O, Diebold M. Filiform polyposis: A benign entity? Case report and literature review. Pathol Res Pract. 2014;210:189-93 pubmed 出版商
  33. Li M, Zhang Q, Liu L, Lu W, Wei H, Li R, et al. Expression of the mismatch repair gene hMLH1 is enhanced in non-small cell lung cancer with EGFR mutations. PLoS ONE. 2013;8:e78500 pubmed 出版商
  34. Kucherlapati M, Esfahani S, Habibollahi P, Wang J, Still E, Bronson R, et al. Genotype directed therapy in murine mismatch repair deficient tumors. PLoS ONE. 2013;8:e68817 pubmed 出版商
  35. Donada M, Bonin S, Barbazza R, Pettirosso D, Stanta G. Management of stage II colon cancer - the use of molecular biomarkers for adjuvant therapy decision. BMC Gastroenterol. 2013;13:36 pubmed 出版商
  36. Campos Vega R, García Gasca T, Guevara González R, Ramos Gomez M, Oomah B, Loarca Pina G. Human gut flora-fermented nondigestible fraction from cooked bean ( Phaseolus vulgaris L.) modifies protein expression associated with apoptosis, cell cycle arrest, and proliferation in human adenocarcinoma colon cancer cells. J Agric Food Chem. 2012;60:12443-50 pubmed 出版商
  37. Coppola D, Nicosia S, Doty A, Sellers T, Lee J, Fulp J, et al. Uncertainty in the utility of immunohistochemistry in mismatch repair protein expression in epithelial ovarian cancer. Anticancer Res. 2012;32:4963-9 pubmed
  38. Couronné L, Ruminy P, Waultier Rascalou A, Rainville V, Cornic M, Picquenot J, et al. Mutation mismatch repair gene deletions in diffuse large B-cell lymphoma. Leuk Lymphoma. 2013;54:1079-86 pubmed 出版商
  39. Helal T, Fadel M, El Thobbani A, El Sarhi A. Immunoexpression of p53 and hMSH2 in oral squamous cell carcinoma and oral dysplastic lesions in Yemen: relationship to oral risk habits and prognostic factors. Oral Oncol. 2012;48:120-4 pubmed 出版商
  40. Gatalica Z, Lilleberg S, Monzon F, Koul M, Bridge J, Knezetic J, et al. Renal medullary carcinomas: histopathologic phenotype associated with diverse genotypes. Hum Pathol. 2011;42:1979-88 pubmed 出版商
  41. Martin S, McCabe N, Mullarkey M, Cummins R, Burgess D, Nakabeppu Y, et al. DNA polymerases as potential therapeutic targets for cancers deficient in the DNA mismatch repair proteins MSH2 or MLH1. Cancer Cell. 2010;17:235-48 pubmed 出版商
  42. Cossio S, Koehler Santos P, Pessini S, Mónego H, Edelweiss M, Meurer L, et al. Clinical and histomolecular endometrial tumor characterization of patients at-risk for Lynch syndrome in South of Brazil. Fam Cancer. 2010;9:131-9 pubmed 出版商
  43. Mei M, Deng D, Liu T, Sang X, Lu X, Xiang H, et al. Clinical implications of microsatellite instability and MLH1 gene inactivation in sporadic insulinomas. J Clin Endocrinol Metab. 2009;94:3448-57 pubmed 出版商
  44. Tobón Arroyave S, Flórez Moreno G, Jaramillo Cárdenas J, Arango Uribe J, Isaza Guzmán D, Rendón Henao J. Expression of hMLH1 and hMSH2 proteins in pleomorphic adenoma of minor salivary glands: relationship with clinical and histologic findings. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009;108:227-36 pubmed 出版商
  45. Arabi H, Guan H, Kumar S, Cote M, Bandyopadhyay S, Bryant C, et al. Impact of microsatellite instability (MSI) on survival in high grade endometrial carcinoma. Gynecol Oncol. 2009;113:153-8 pubmed 出版商
  46. Permuth Wey J, Boulware D, Valkov N, Livingston S, Nicosia S, Lee J, et al. Sampling strategies for tissue microarrays to evaluate biomarkers in ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2009;18:28-34 pubmed 出版商
  47. Bendardaf R, Lamlum H, Ristamaki R, Syrjanen K, Pyrhonen S. Oncoprotein Bcl-2 and microsatellite instability are associated with disease-free survival and treatment response in colorectal cancer. Oncol Rep. 2008;20:999-1004 pubmed
  48. Mylona E, Zarogiannos A, Nomikos A, Giannopoulou I, Nikolaou I, Zervas A, et al. Prognostic value of microsatellite instability determined by immunohistochemical staining of hMSH2 and hMSH6 in urothelial carcinoma of the bladder. APMIS. 2008;116:59-65 pubmed 出版商
  49. Li M, Liu L, Wang Z, Wang L, Liu Z, Xu G, et al. Overexpression of hMSH2 and hMLH1 protein in certain gastric cancers and their surrounding mucosae. Oncol Rep. 2008;19:401-6 pubmed
  50. Yoon S, Ku J, Shin Y, Kim K, Choi J, Jang E, et al. Hereditary nonpolyposis colorectal cancer in endometrial cancer patients. Int J Cancer. 2008;122:1077-81 pubmed
  51. Bendardaf R, Lamlum H, Ristamaki R, Korkeila E, Syrjanen K, Pyrhonen S. Thymidylate synthase and microsatellite instability in colorectal cancer: implications for disease free survival, treatment response and survival with metastases. Acta Oncol. 2008;47:1046-53 pubmed
  52. Taylor N, Zighelboim I, Huettner P, Powell M, Gibb R, Rader J, et al. DNA mismatch repair and TP53 defects are early events in uterine carcinosarcoma tumorigenesis. Mod Pathol. 2006;19:1333-8 pubmed
  53. Edelmann J, Richter K, Hanel C, Hering S, Horn L. X chromosomal and autosomal loss of heterozygosity and microsatellite instability in human cervical carcinoma. Int J Gynecol Cancer. 2006;16:1248-53 pubmed
  54. Kerber R, Neklason D, Samowitz W, Burt R. Frequency of familial colon cancer and hereditary nonpolyposis colorectal cancer (Lynch syndrome) in a large population database. Fam Cancer. 2005;4:239-44 pubmed
  55. Chen Z, Ritter J, Wang H. Differential expression of alpha-methylacyl coenzyme A racemase in adenocarcinomas of the small and large intestines. Am J Surg Pathol. 2005;29:890-6 pubmed
  56. Ricciardiello L, Ceccarelli C, Angiolini G, Pariali M, Chieco P, Paterini P, et al. High thymidylate synthase expression in colorectal cancer with microsatellite instability: implications for chemotherapeutic strategies. Clin Cancer Res. 2005;11:4234-40 pubmed
  57. Aust D, Haase M, Dobryden L, Markwarth A, Löhrs U, Wittekind C, et al. Mutations of the BRAF gene in ulcerative colitis-related colorectal carcinoma. Int J Cancer. 2005;115:673-7 pubmed
  58. Charara M, Edmonston T, Burkholder S, Walters R, Anne P, Mitchell E, et al. Microsatellite status and cell cycle associated markers in rectal cancer patients undergoing a combined regimen of 5-FU and CPT-11 chemotherapy and radiotherapy. Anticancer Res. 2004;24:3161-7 pubmed
  59. Boman B, Walters R, Fields J, Kovatich A, Zhang T, Isenberg G, et al. Colonic crypt changes during adenoma development in familial adenomatous polyposis: immunohistochemical evidence for expansion of the crypt base cell population. Am J Pathol. 2004;165:1489-98 pubmed
  60. Buttin B, Powell M, Mutch D, Rader J, Herzog T, Gibb R, et al. Increased risk for hereditary nonpolyposis colorectal cancer-associated synchronous and metachronous malignancies in patients with microsatellite instability-positive endometrial carcinoma lacking MLH1 promoter methylation. Clin Cancer Res. 2004;10:481-90 pubmed